DAIC

JUNE 4, 2024

milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.

Medicare 104

Medicare Plaque Reimbursement Cardiovascular Disease 104

DAIC

JULY 18, 2024

a leader in non-invasive artificial intelligence (AI) heart care solutions, introduced the next generation HeartFlow Plaque Analysis with an interactive experience. Having access to a patient’s whole coronary picture, with both quantified plaque and physiology, is a game changer as a clinician. F.A.C.C.

Coronary Artery Disease 111

Coronary Artery Disease Plaque Technology Medicare 111

DAIC

OCTOBER 15, 2024

15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQ image analysis software, beginning Nov. tim.hodson Tue, 10/15/2024 - 12:12 Oct. For more information, please visit elucid.com.

Medicare 52

Medicare Plaque Chest Pain Coronary Artery Disease 52

DAIC

OCTOBER 16, 2024

15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). tim.hodson Wed, 10/16/2024 - 12:36 Oct. The four contractors for the U.S.

CMS 52

CMS Medicare Plaque Chest Pain 52

DAIC

DECEMBER 5, 2024

This funding will allow us to expand our commercial reach, which is especially germane following our recent achievements in attaining Medicare coverage and a CPT Category I code for advanced plaque analysis. Until Cleerly, healthcare providers have had no way to easily and completely assess plaque burden in a non-invasive manner.

Coronary Artery Disease 52

Coronary Artery Disease Medicare Technology Plaque 52

DAIC

JUNE 18, 2024

The breakthrough designation, according to the Milpitas, CA-based technology company, is for an indication to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. of the U.S. population.

Coronary Artery Disease 105

Coronary Artery Disease Technology Stent Stents 105

DAIC

MAY 8, 2024

Longitudinal assessment of safety of FEMOROPOPLITEAL endovascular treatment with paclitaxel-coated devices among Medicare beneficiaries.” European Journal of Vascular and Endovascular Surgery, vol. 301–302, [link]. 3 Secemsky, Eric A., JAMA Internal Medicine, vol. 1071, [link]. 4 Bradbury, Andrew W, et al. “A

Coronary Artery Disease 111

Coronary Artery Disease Chest Pain Ischemia Myocardial Infarction 111